Identify tests predicting Parkinson progression
- Trial ID
- NCT04477785
- Official Title
- The Parkinson's Progression Markers Initiative (PPMI) Clinical - Establishing a Deeply Phenotyped PD Cohort
- Goal
- Identify tests predicting Parkinson progression
- Status
- RECRUITING
- Sponsor
- Michael J. Fox Foundation for Parkinson's Research
- Study Type
- OBSERVATIONAL
- Enrollment
- 4500 participants
- Conditions
- Parkinson Disease
Plain-Language Summary
The goal is to identify imaging, genetic, fluid, and clinical markers that track and predict Parkinson's progression so we can diagnose earlier and design better, more targeted trials. Instead of testing a drug, the study deeply profiles participants with DaTscan SPECT to measure dopamine transporter loss, genetic testing for LRRK2/GBA/SNCA and other variants, lumbar punctures for CSF biomarkers (like alpha-synuclein), MRI, and repeated clinical and remote assessments; DAT imaging is used for eligibility but results are not revealed to participant or site. They are looking for several groups: healthy controls age 57 and up, people with early PD diagnosed within 2 years who are generally not yet on levodopa or other PD meds (age 30+), genetic-subtype PD cases, and prodromal high-risk adults (typically 60+), with common exclusions for dementia, recent dopamine-blocking drugs, anticoagulation or any condition that would make lumbar puncture unsafe.
Locations
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Barrow Neurological Institute, Phoenix, Arizona, United States
- Mayo Foundation for Medical Education and Research, Scottsdale, Arizona, United States
- Banner Research Institute, Sun City, Arizona, United States
- University of California San Diego, La Jolla, California, United States
- Keck School of Medicine of USC, Los Angeles, California, United States
- University of California, San Francisco, San Francisco, California, United States
- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Institute For Neurodegenerative Disorders, New Haven, Connecticut, United States
- Parkinson's Disease& Movement Disorder Center of Boca Raton, Boca Raton, Florida, United States
- University of Florida, Gainesville, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Emory University School of Medicine, Atlanta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Boston University, Boston, Massachusetts, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States
And 30 more locations.
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to identify imaging, genetic, fluid, and clinical markers that track and predict Parkinson's progression so we can diagnose earlier and design better, more targeted trials. Instead of testing a drug, the study deeply profiles participants with DaTscan SPECT to measure dopamine transporter loss, genetic testing for LRRK2/GBA/SNCA and other variants, lumbar punctures for CSF biomarkers (like alpha-synuclein), MRI, and repeated clinical and remote assessments; DAT imaging is used for eligibility but results are not revealed to participant or site. They are looking for several groups: healthy controls age 57 and up, people with early PD diagnosed within 2 years who are generally not yet on levodopa or other PD meds (age 30+), genetic-subtype PD cases, and prodromal high-risk adults (typically 60+), with common exclusions for dementia, recent dopamine-blocking drugs, anticoagulation or any condition that would make lumbar puncture unsafe.
- Who can participate?
- Participants must be at least 30 Years.
- Where is this trial located?
- This trial is recruiting at 50 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 13 years and 5 months.